Literature DB >> 14990591

Guidelines for HER2 testing in the UK.

E D Hsi, R R Tubbs.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14990591      PMCID： PMC1770236          DOI： 10.1136/jcp.2003.009308

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN： 0021-9746            Impact factor:   3.411


× No keyword cloud information.
  9 in total

1.  Gold-facilitated in situ hybridization: a bright-field autometallographic alternative to fluorescence in situ hybridization for detection of Her-2/neu gene amplification.

Authors:  Raymond Tubbs; James Pettay; Marek Skacel; Richard Powell; Mark Stoler; Patrick Roche; James Hainfeld
Journal:  Am J Pathol       Date:  2002-05       Impact factor: 4.307

Review 2.  Clinical laboratory assays for HER-2/neu amplification and overexpression: quality assurance, standardization, and proficiency testing.

Authors: 
Journal:  Arch Pathol Lab Med       Date:  2002-07       Impact factor: 5.534

3.  Best Practice No 176: Updated recommendations for HER2 testing in the UK.

Authors:  I O Ellis; J Bartlett; M Dowsett; S Humphreys; B Jasani; K Miller; S E Pinder; A Rhodes; R Walker
Journal:  J Clin Pathol       Date:  2004-03       Impact factor: 3.411

4.  Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry.

Authors:  G Pauletti; S Dandekar; H Rong; L Ramos; H Peng; R Seshadri; D J Slamon
Journal:  J Clin Oncol       Date:  2000-11-01       Impact factor: 44.544

5.  Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples.

Authors:  M Tanner; D Gancberg; A Di Leo; D Larsimont; G Rouas; M J Piccart; J Isola
Journal:  Am J Pathol       Date:  2000-11       Impact factor: 4.307

6.  Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831.

Authors:  Patrick C Roche; Vera J Suman; Robert B Jenkins; Nancy E Davidson; Silvana Martino; Peter A Kaufman; Ferdinand K Addo; Bronagh Murphy; James N Ingle; Edith A Perez
Journal:  J Natl Cancer Inst       Date:  2002-06-05       Impact factor: 13.506

Review 7.  Anticancer antibodies.

Authors:  Jeffrey S Ross; Karen Gray; Gary S Gray; Peter J Worland; Mark Rolfe
Journal:  Am J Clin Pathol       Date:  2003-04       Impact factor: 2.493

8.  Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: a comparative study involving results from laboratories in 21 countries.

Authors:  Anthony Rhodes; Bharat Jasani; Elizabeth Anderson; Andrew R Dodson; André J Balaton
Journal:  Am J Clin Pathol       Date:  2002-09       Impact factor: 2.493

9.  Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression.

Authors:  M F Press; G Hung; W Godolphin; D J Slamon
Journal:  Cancer Res       Date:  1994-05-15       Impact factor: 12.701
  9 in total
  9 in total

Review 1.  Virtual microscopy as an enabler of automated/quantitative assessment of protein expression in TMAs.

Authors:  Catherine Conway; Lynne Dobson; Anthony O'Grady; Elaine Kay; Sean Costello; Daniel O'Shea
Journal:  Histochem Cell Biol       Date:  2008-08-05       Impact factor: 4.304

2.  Overexpression/amplification of HER-2/neu is uncommon in hepatocellular carcinoma.

Authors:  Z-H Xian; S-H Zhang; W-M Cong; W-Q Wu; M-C Wu
Journal:  J Clin Pathol       Date:  2005-05       Impact factor: 3.411

3.  Image analysis as an adjunct to manual HER-2 immunohistochemical review: a diagnostic tool to standardize interpretation.

Authors:  Lynne Dobson; Catherine Conway; Alan Hanley; Alex Johnson; Sean Costello; Anthony O'Grady; Yvonne Connolly; Hilary Magee; Daniel O'Shea; Michael Jeffers; Elaine Kay
Journal:  Histopathology       Date:  2010-06-24       Impact factor: 5.087

4.  Analytical Validation of a Highly Quantitative, Sensitive, Accurate, and Reproducible Assay (HERmark) for the Measurement of HER2 Total Protein and HER2 Homodimers in FFPE Breast Cancer Tumor Specimens.

Authors:  Jeffrey S Larson; Laurie J Goodman; Yuping Tan; Lisa Defazio-Eli; Agnes C Paquet; Jennifer W Cook; Amber Rivera; Kristi Frankson; Jolly Bose; Lili Chen; Judy Cheung; Yining Shi; Sarah Irwin; Linda D B Kiss; Weidong Huang; Shannon Utter; Thomas Sherwood; Michael Bates; Jodi Weidler; Gordon Parry; John Winslow; Christos J Petropoulos; Jeannette M Whitcomb
Journal:  Patholog Res Int       Date:  2010-06-28

5.  Serum HER-2 concentration in patients with primary breast cancer.

Authors:  S-Y Kong; J H Kang; Y Kwon; H-S Kang; K-W Chung; S H Kang; D H Lee; J Ro; E S Lee
Journal:  J Clin Pathol       Date:  2006-02-03       Impact factor: 3.411

6.  Multiparameter DNA content analysis identifies distinct groups in primary breast cancer.

Authors:  J H S Dayal; M J Sales; W E Corver; C A Purdie; L B Jordan; P R Quinlan; L Baker; N T ter Haar; N R Pratt; A M Thompson
Journal:  Br J Cancer       Date:  2013-02-14       Impact factor: 7.640

7.  p16 expression correlates with basal-like triple-negative breast carcinoma.

Authors:  Amany A Abou-Bakr; Hany I Eldweny
Journal:  Ecancermedicalscience       Date:  2013-05-14

8.  Observer performance in the use of digital and optical microscopy for the interpretation of tissue-based biomarkers.

Authors:  Marios A Gavrielides; Catherine Conway; Neil O'Flaherty; Brandon D Gallas; Stephen M Hewitt
Journal:  Anal Cell Pathol (Amst)       Date:  2014-11-11       Impact factor: 2.916

9.  External Quality Assessment (EQA) program for the preanalytical and analytical immunohistochemical determination of HER2 in breast cancer: an experience on a regional scale.

Authors:  Irene Terrenato; Vincenzo Arena; Sara Pizzamiglio; Ilaria Pennacchia; Letizia Perracchio; Simonetta Buglioni; Cristiana Ercolani; Francesca Sperati; Leopoldo Costarelli; Elena Bonanno; Daniela Baldini; Silvia Candia; Anna Crescenzi; Antonella Dal Mas; Claudio Di Cristofano; Vito Gomes; Lucia Rosalba Grillo; Paola Pasquini; Maria Nicoletta Pericoli; Maria Teresa Ramieri; Domenica Di Stefano; Luigi Ruco; Stefania Scarpino; Domenico Vitolo; Giulia d'Amati; Angelo Paradiso; Paolo Verderio; Marcella Mottolese
Journal:  J Exp Clin Cancer Res       Date:  2013-08-21
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.